naratriptan has been researched along with Abdominal Migraine in 112 studies
naratriptan: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack." | 7.71 | Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. ( Goadsby, PJ; Jiang, K; Lines, CR; Lipton, RB; Massiou, H; McCarroll, KA; Pascual, J; Vandormael, K, 2001) |
| "Using the Marketscan database, the risk of major birth defects was ascertained in live-born infants whose birth mothers were exposed to sumatriptan, naratriptan, or sumatriptan/naproxen during pregnancy." | 3.88 | Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study. ( Bollinger, L; Cangialose, C; Chia, V; Mikol, DD; Xue, F; Yusuf, A, 2018) |
| "Accumulated data suggest that exposure to sumatriptan during pregnancy does not increase the risk of birth defects above the baseline rate." | 3.76 | Safety of triptans for migraine headaches during pregnancy and breastfeeding. ( Bozzo, P; Duong, S; Einarson, A; Nordeng, H, 2010) |
| "This case report describes for the first time acute coronary syndrome in a 67-year old patient after oral intake of naratriptan for migraine." | 3.75 | Triptans and troponin: a case report. ( Schneemann, M; Weder, CR, 2009) |
| "To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack." | 3.71 | Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. ( Goadsby, PJ; Jiang, K; Lines, CR; Lipton, RB; Massiou, H; McCarroll, KA; Pascual, J; Vandormael, K, 2001) |
| "1997, sumatriptan-treated migraineurs had significantly higher depression PCRs (22." | 3.70 | Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness? ( Croft, P; Frischer, M; Goadsby, PJ; Millson, D, 2000) |
| "MRM was defined as any migraine beginning during the perimenstrual period (PMP)." | 2.73 | Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. ( Ames, MH; Brandes, JL; Diamond, M; Smith, T, 2007) |
| "Naratriptan was marketed for the treatment of migraine attacks as the "gentle triptan" in a low oral dose of 2." | 2.72 | Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review. ( Tfelt-Hansen, P, 2021) |
| "naratriptan in the acute treatment of migraine." | 2.71 | Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. ( Bordini, CA; Garcia-Ramos, G; Hettiarachchi, J; Hilliard, B; Leston, J; MacGregor, EA, 2003) |
| "However, the incidence of withdrawal symptoms and consumption of rescue drugs was higher among the patients who did not take regular medications during the first 6 days (P = 0." | 2.71 | Out-patient detoxification in chronic migraine: comparison of strategies. ( Krymchantowski, AV; Moreira, PF, 2003) |
| "Menstrual migraines are particularly difficult-totreat." | 2.71 | Naratriptan in the short-term prophylaxis of pure menstrual migraine. ( Allais, G; Benedetto, C; Bussone, G; D'Amico, D; Grazzi, L; Moschiano, F; Roncolato, M; Usai, S, 2005) |
| "Naratriptan is a novel 5-HT1 agonist developed to treat acute migraine." | 2.70 | Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. ( Christensen, ML; Eades, SK; Fuseau, E; Hak, LJ; Kempsford, RD; Phelps, SJ, 2001) |
| "Naratriptan, 2." | 2.70 | Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. ( Batenhorst, A; Jöbsis, M; Landy, S; Lipton, RB; Mannix, LK; Newman, L; O'Quinn, S; Putnam, DG; Silberstein, S; Watson, C, 2001) |
| ") In a subset of patients experiencing headache relief after 2 attacks, headache recurrence 4 to 24 hours after initial dosing was reported by 55 naratriptan- and 77 sumatriptan-treated patients (41% and 57%, respectively; P = 0." | 2.69 | Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. ( Becker, W; Boswell, D; Crisp, A; Göbel, H; Hauge, T; Mihout, B; Niewold, J; Tørring, J; Winter, P, 2000) |
| "Naratriptan for first-line migraine therapy was preferred by most patients over previous nontriptan therapy." | 2.69 | Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents. ( Bort, T; Cady, R; Cervi, M; Pangtay, D; Powers, C; Szeto, S, 2000) |
| "Rizatriptan was more effective than naratriptan." | 2.69 | Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. ( Allen, C; Bomhof, M; Legg, N; Patel, K; Paz, J; Vandormael, K, 1999) |
| "Naratriptan was also more effective than placebo in reducing clinical disability and the incidences of nausea, photophobia, and phonophobia." | 2.68 | Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. ( Asgharnejad, M; Laurenza, A; Mathew, NT; Peykamian, M, 1997) |
| "Naproxen is a non-steroidal anti-inflammatory drug (NSAID); its efficacy in acute migraine has not been established by systematic reviews." | 2.49 | Naproxen with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Law, S; Moore, RA, 2013) |
| "Naratriptan 1 mg b." | 2.47 | Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. ( Tfelt-Hansen, PC, 2011) |
| "The annual cost of migraine is euro27 billion in Europe, $US1." | 2.44 | Over-the-counter triptans for migraine : what are the implications? ( Steiner, TJ; Tfelt-Hansen, P, 2007) |
| "The clinical efficacy in migraine was compared for oral and subcutaneous sumatriptan and naratriptan." | 2.44 | Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. ( Tfelt-Hansen, P, 2007) |
| "Naratriptan has also a therapeutic effect on the nausea of migraine, possibly exerting its action at the level of the nucleus tractus solitarius via the same mechanisms by which it inhibits trigeminovascular nociceptive input." | 2.43 | Preclinical neuropharmacology of naratriptan. ( Lambert, GA, 2005) |
| "Naratriptan 2." | 2.42 | Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. ( Ashcroft, DM; Millson, D, 2004) |
| "Oral rizatriptan 10 mg was more effective than oral sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures of pain-free response at 2 hours, symptom-free response at 2 hours, and 24-hour sustained pain-free response." | 2.41 | Comparison of rizatriptan and other triptans on stringent measures of efficacy. ( Adelman, JU; Diener, HC; Ferrari, MD; Lines, CR; Lipton, RB; McCarroll, KA; Vandormael, K, 2001) |
| "Migraine headaches are a common medical problem that physicians frequently encounter in their practice." | 2.41 | Treatment of acute migraine attacks. ( Weintraub, JR, 2000) |
| "Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies." | 2.41 | Newer intranasal migraine medications. ( Logemann, CD; Rankin, LM, 2000) |
| "Naratriptan is a selective 5-HT(1B/1D) receptor agonist, with a high affinity at the 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor subtypes." | 2.41 | Naratriptan. ( Massiou, H, 2001) |
| "There exist increasing options for migraine treatment that may further improve the clinical effects of the older and newer triptans through early treatment of migraine at the stages of mild migraine pain, or even during the prodromal phase of the attack." | 2.41 | Acute treatment of migraine and the role of triptans. ( Freitag, FG, 2001) |
| "Thus sumatriptan has become the de facto gold standard and will be thus employed here." | 2.40 | The scientific basis of medication choice in symptomatic migraine treatment. ( Goadsby, PJ, 1999) |
| "Naratriptan has been recently approved for acute oral migraine therapy." | 2.40 | Naratriptan: an alternative for migraine. ( Dulli, DA, 1999) |
| "The other new migraine drugs zolmitriptan, naratriptan, rizatriptan and eletriptan differ in their pharmacological profiles, which translates into minor differences in efficacy, headache recurrence and side-effects." | 2.40 | Acute management of migraine: triptans and beyond. ( Diener, HC; Limmroth, V, 1999) |
| "Imaging migraine premonitory studies show increased midbrain activation consistent with the ventral tegmental area, an area involved in pain modulation and hedonic feeding." | 1.72 | Pharmacological modulation of ventral tegmental area neurons elicits changes in trigeminovascular sensory processing and is accompanied by glycemic changes: Implications for migraine. ( Akerman, S; Goadsby, PJ; Holland, PR; Martins-Oliveira, M; Tavares, I, 2022) |
| "Patients with episodic and chronic migraine who experienced continuous and prolonged attacks for more than 72 hours were treated with dexamethasone (4 mg orally twice daily for 3 days), ketorolac (60 mg intramuscularly), bilateral nerve blocks (1-2% lidocaine, 0." | 1.56 | Unrecognized challenges of treating status migrainosus: An observational study. ( Ashina, S; Burstein, R; Chua, A; Grosberg, B; Iljazi, A; Melo-Carrillo, A; Rich-Fiondella, R; Veronesi, M, 2020) |
| "Naratriptan was taken before the patient went to bed." | 1.46 | Naratriptan in the Prophylactic Treatment of Cluster Headache. ( Araki, N; Asano, Y; Ito, Y; Kato, Y; Maruki, Y; Mitsufuji, T; Sakai, F; Shimazu, T; Tanahashi, N; Yamamoto, T, 2017) |
| "Familial hemiplegic migraine type 1 (FHM-1) is a monogenic subtype of migraine with aura caused by missense mutations in the CACNA1A gene, which encodes the pore-forming α1 subunit of voltage-gated neuronal CaV2." | 1.40 | Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: a Fos protein study. ( Akerman, S; Andreou, AP; Ferrari, MD; Goadsby, PJ; Holland, PR; Lasalandra, MP; Moon, H; Park, J; van den Maagdenberg, AM, 2014) |
| "Naratriptan hydrochloride was dissolved immediately after disintegration, hence facilitating buccal absorption of the active pharmaceutical ingredient." | 1.40 | Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride. ( Führling, C; Gieseler, H; Stange, U, 2014) |
| "He suffered from frequent attacks of migraine-like headache (3-7 per month), pulsating in nature associated with nausea." | 1.38 | Migraine-like headache in a patient with complement 1 inhibitor deficient hereditary angioedema. ( Chung, JY; Kim, M, 2012) |
| "Chronic migraine (CM) is a common disorder, affecting 2% to 3% of the general population." | 1.34 | Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. ( Cavalheiro, EA; Naffah-Mazzacoratti, Mda G; Peres, MF; Senne Soares, CA; Vieira, DS; Zukerman, E, 2007) |
| "In this report, a case with vitamin B12 deficiency showing a temporary confusion depending on the usage of naratriptan during the migraine attack was presented." | 1.34 | Temporary confusion depending on the usage of naratriptan. ( Gokalp, O; Gultekin, F; Incekara, F; Koyuncuoglu, HR; Kutluhan, S; Sozen, A; Tak, R, 2007) |
| "Migraine is a prevalent neurological disorder that can be alleviated by specific treatment for acute headaches, in particular, the triptans, including naratriptan." | 1.34 | [The Vigimig study of naratriptan use in general practice]. ( Allaert, FA; Druais, PL; El Hasnaoui, A; Lanteri-Minet, M; Nachit-Ouinekh, F, 2007) |
| "The treatment of migraine consists of the acute treatment of the migraine attack and prophylactic measures for either pharmacological or non-pharmacological management." | 1.33 | [Prophylactic measures and acute treatment of migraine]. ( Göbel, H; Heinze, A; Heinze-Kuhn, K, 2006) |
| " The analysis was based on phase I pharmacokinetic naratriptan data, sumatriptan pharmacodynamic data, and naratriptan preclinical (animal) potency information, together with general knowledge as to how migraine affects oral absorption." | 1.33 | Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan. ( Aarons, L; Gueorguieva, I; Nestorov, IA; Rowland, M, 2005) |
| "Eletriptan 40 mg also was found to have the lowest total triptan cost to successfully treat 100 patients." | 1.33 | Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. ( Healey, PJ; Mullins, CD; Perfetto, EM; Subedi, PR; Weis, KA, 2005) |
| "Ischemic colitis has not been reported in association with naratriptan therapy." | 1.33 | Ischemic colitis associated with naratriptan and oral contraceptive use. ( Charles, JA; Pullicino, PM; Shroff, Y; Stoopack, PM, 2005) |
| " Disease dynamics must be considered to evaluate treatment response adequately and optimise the dosing regimen in migraine." | 1.33 | A model-based approach to treatment comparison in acute migraine. ( Danhof, M; Della Pasqua, O; Maas, HJ, 2006) |
| "Physicians had to document the migraine history, and to report symptoms and health care in a structured case report form." | 1.32 | [A descriptive analysis of naratriptan use among migraineurs in ambulatory medicine]. ( Brudon-Mollard, F; Chemali-Hudry, J; Druais, PL; El Hasnaoui, A; Giacomino, A; Hinault, P; Lanteri-Minet, M; Zaïm, M, 2003) |
| "The treatment of chronic migraine often poses a major challenge to the clinician." | 1.32 | Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. ( Bigal, ME; Feleppa, M; Rapoport, AM; Sheftell, FD; Tepper, SJ; Volcy, M, 2003) |
| "In direct head-to-head comparative clinical trials, oral rizatriptan 10 mg enabled more migraine sufferers to function normally at 2 h after dosing than oral sumatriptan, naratriptan, and zolmitriptan." | 1.31 | Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. ( Bussone, G; D'Amico, D; Gerth, W; Lines, CR; McCarroll, KA, 2002) |
| "The overall incidence of headache recurrence is low after naratriptan, 2." | 1.31 | Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. ( O'Quinn, S; Pait, D; Sheftell, F; Watson, C; Winter, P, 2000) |
| "Four hundred and seventeen (417) migraine patients treated 15,301 migraine attacks over the course of the study." | 1.31 | Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group. ( Bomhof, MA; Hassani, H; Heywood, J; Pradalier, A; Thaventhiran, L; Winter, P, 2000) |
| "Modulatory effects of the new antimigraine drug naratriptan, a 5-HT(1)-receptor-agonist, on neurons of the nucleus raphé magnus were examined in rat by extracellular recordings." | 1.31 | Modulation of neuronal activity in the nucleus raphé magnus by the 5-HT(1)-receptor agonist naratriptan in rat. ( Chiang, CY; Ellrich, J; Hu, JW; Messlinger, K, 2001) |
| "Naratriptan is a newly developed triptan shown to be effective in the treatment of migraine." | 1.31 | Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. ( Black, L; Caro, G; Caro, JJ; Getsios, D; Raggio, G, 2001) |
| "Rizatriptan was associated with significantly lower triptan tablet use and additional medication use per attack than the other triptans." | 1.31 | Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. ( Fité, B; López-Gil, A; Pascual, J, 2002) |
| "Of the prophylactic antimigraine drugs tested, methysergide and lisuride behaved as efficacious agonists (Emax > or = 90% relative to 5-HT) whereas pitozifen and (-)propranolol acted as a partial agonist (60%) and an antagonist, respectively." | 1.30 | Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. ( Audinot-Bouchez, V; Chaput, C; Conte, C; Lavielle, G; Lochon, S; Millan, MJ; Newman-Tancredi, A; Verrièle, L, 1997) |
| "The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting from coronary artery constriction." | 1.30 | Coronary side-effect potential of current and prospective antimigraine drugs. ( Bax, WA; Ferrari, MD; MaassenVanDenBrink, A; Reekers, M; Saxena, PR, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (16.07) | 18.2507 |
| 2000's | 74 (66.07) | 29.6817 |
| 2010's | 16 (14.29) | 24.3611 |
| 2020's | 4 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Newman-Tancredi, A | 1 |
| Conte, C | 1 |
| Chaput, C | 1 |
| Verrièle, L | 1 |
| Audinot-Bouchez, V | 1 |
| Lochon, S | 1 |
| Lavielle, G | 1 |
| Millan, MJ | 1 |
| Martins-Oliveira, M | 1 |
| Akerman, S | 2 |
| Holland, PR | 2 |
| Tavares, I | 1 |
| Goadsby, PJ | 8 |
| Iljazi, A | 1 |
| Chua, A | 1 |
| Rich-Fiondella, R | 1 |
| Veronesi, M | 1 |
| Melo-Carrillo, A | 1 |
| Ashina, S | 1 |
| Burstein, R | 1 |
| Grosberg, B | 1 |
| Amundsen, S | 1 |
| Nordeng, H | 2 |
| Fuskevåg, OM | 1 |
| Nordmo, E | 1 |
| Sager, G | 1 |
| Spigset, O | 1 |
| Tfelt-Hansen, P | 5 |
| Ito, Y | 1 |
| Mitsufuji, T | 1 |
| Asano, Y | 1 |
| Shimazu, T | 1 |
| Kato, Y | 1 |
| Tanahashi, N | 1 |
| Maruki, Y | 1 |
| Sakai, F | 2 |
| Yamamoto, T | 1 |
| Araki, N | 1 |
| Kikui, S | 1 |
| Takeshima, T | 2 |
| Yusuf, A | 1 |
| Chia, V | 1 |
| Xue, F | 1 |
| Mikol, DD | 1 |
| Bollinger, L | 1 |
| Cangialose, C | 1 |
| Schneemann, M | 2 |
| Ruggieri, F | 1 |
| Law, S | 1 |
| Derry, S | 1 |
| Moore, RA | 1 |
| Park, J | 1 |
| Moon, H | 1 |
| Lasalandra, MP | 1 |
| Andreou, AP | 1 |
| Ferrari, MD | 3 |
| van den Maagdenberg, AM | 1 |
| Jacobs, HS | 1 |
| Stange, U | 1 |
| Führling, C | 1 |
| Gieseler, H | 1 |
| Kraya, T | 1 |
| Schlitt, A | 1 |
| Tokuoka, K | 1 |
| Takayanagi, R | 1 |
| Suzuki, Y | 1 |
| Watanabe, M | 1 |
| Kitagawa, Y | 1 |
| Yamada, Y | 1 |
| Macone, AE | 1 |
| Perloff, MD | 1 |
| Ravikumar, K | 1 |
| Sridhar, B | 1 |
| Krishnan, H | 1 |
| Singh, AN | 1 |
| Weder, CR | 1 |
| Jamieson, DG | 1 |
| Beau-Salinas, F | 1 |
| Jonville-Béra, AP | 1 |
| Cissoko, H | 1 |
| Bensouda-Grimaldi, L | 1 |
| Autret-Leca, E | 1 |
| Westgeest, HM | 1 |
| Akol, H | 1 |
| Schreuder, TC | 1 |
| Duong, S | 1 |
| Bozzo, P | 1 |
| Einarson, A | 1 |
| Tfelt-Hansen, PC | 1 |
| Chung, JY | 1 |
| Kim, M | 1 |
| Tepper, SJ | 2 |
| Rapoport, AM | 2 |
| Sheftell, FD | 2 |
| Bussone, G | 2 |
| D'Amico, D | 2 |
| McCarroll, KA | 3 |
| Gerth, W | 1 |
| Lines, CR | 3 |
| Massiou, H | 4 |
| Macaigne, G | 1 |
| Simon, P | 1 |
| Auriault, ML | 1 |
| Boivin, JF | 1 |
| Froguel, E | 1 |
| Chayette, C | 1 |
| Cheaib, S | 1 |
| Deplus, R | 1 |
| Adelman, JU | 2 |
| Lewit, EJ | 1 |
| Bigal, ME | 1 |
| Volcy, M | 1 |
| Feleppa, M | 1 |
| Brudon-Mollard, F | 1 |
| Druais, PL | 2 |
| Giacomino, A | 1 |
| Hinault, P | 1 |
| Lanteri-Minet, M | 2 |
| Zaïm, M | 1 |
| Chemali-Hudry, J | 1 |
| El Hasnaoui, A | 2 |
| Stronks, DL | 1 |
| Tulen, JH | 1 |
| Bussmann, HB | 1 |
| Mulder, LJ | 1 |
| Passchier, J | 1 |
| Létienne, R | 1 |
| Verscheure, Y | 1 |
| John, GW | 1 |
| Garcia-Ramos, G | 1 |
| MacGregor, EA | 1 |
| Hilliard, B | 1 |
| Bordini, CA | 1 |
| Leston, J | 1 |
| Hettiarachchi, J | 1 |
| Boers, PM | 1 |
| Donaldson, C | 1 |
| Zagami, AS | 2 |
| Lambert, GA | 2 |
| Krymchantowski, AV | 1 |
| Moreira, PF | 1 |
| Ashcroft, DM | 1 |
| Millson, D | 2 |
| Iizuka, T | 1 |
| Barrows, C | 1 |
| Saunders, W | 1 |
| Austin, R | 1 |
| Putnam, G | 1 |
| Mansbach, H | 1 |
| Nakashima, K | 1 |
| Kowa, H | 1 |
| Morillo, LE | 2 |
| Pascual, J | 3 |
| Muñoz, P | 1 |
| Charles, JA | 1 |
| Pullicino, PM | 1 |
| Stoopack, PM | 1 |
| Shroff, Y | 1 |
| Moschiano, F | 1 |
| Allais, G | 1 |
| Grazzi, L | 1 |
| Usai, S | 1 |
| Benedetto, C | 1 |
| Roncolato, M | 1 |
| Mullins, CD | 1 |
| Weis, KA | 1 |
| Perfetto, EM | 1 |
| Subedi, PR | 1 |
| Healey, PJ | 1 |
| Tietjen, GE | 1 |
| Athanas, K | 1 |
| Utley, C | 1 |
| Herial, NA | 1 |
| Khuder, SA | 1 |
| Gueorguieva, I | 1 |
| Nestorov, IA | 1 |
| Aarons, L | 1 |
| Rowland, M | 1 |
| Jamin, C | 1 |
| Hinzelin, G | 1 |
| Bidaut-Mazel, C | 1 |
| Cuvellier, JC | 1 |
| Joriot, S | 1 |
| Auvin, S | 1 |
| Vallée, L | 1 |
| Shields, KG | 1 |
| Göbel, H | 2 |
| Heinze, A | 1 |
| Heinze-Kuhn, K | 1 |
| Maas, HJ | 1 |
| Danhof, M | 1 |
| Della Pasqua, O | 1 |
| Kunkel, M | 1 |
| Vieira, DS | 1 |
| Naffah-Mazzacoratti, Mda G | 1 |
| Zukerman, E | 1 |
| Senne Soares, CA | 1 |
| Cavalheiro, EA | 1 |
| Peres, MF | 1 |
| Brandes, JL | 1 |
| Smith, T | 1 |
| Diamond, M | 1 |
| Ames, MH | 1 |
| Nachit-Ouinekh, F | 1 |
| Allaert, FA | 1 |
| Steiner, TJ | 1 |
| Kutluhan, S | 1 |
| Incekara, F | 1 |
| Sozen, A | 1 |
| Koyuncuoglu, HR | 1 |
| Tak, R | 1 |
| Gokalp, O | 1 |
| Gultekin, F | 1 |
| Mathew, NT | 1 |
| Asgharnejad, M | 1 |
| Peykamian, M | 1 |
| Laurenza, A | 1 |
| Bomhof, MA | 2 |
| Heywood, J | 2 |
| Pradalier, A | 2 |
| Enahoro, H | 2 |
| Winter, P | 5 |
| Hassani, H | 3 |
| MaassenVanDenBrink, A | 1 |
| Reekers, M | 1 |
| Bax, WA | 1 |
| Saxena, PR | 1 |
| Scholz, MJ | 1 |
| Monseu, G | 1 |
| Sternon, J | 1 |
| Limmroth, V | 2 |
| Kazarawa, Z | 1 |
| Fritsche, G | 1 |
| Diener, HC | 4 |
| Scheen, AJ | 1 |
| Goldstein, D | 1 |
| Dulli, DA | 1 |
| Deleu, D | 2 |
| Hanssens, Y | 2 |
| Bomhof, M | 1 |
| Paz, J | 1 |
| Legg, N | 2 |
| Allen, C | 1 |
| Vandormael, K | 3 |
| Patel, K | 1 |
| Vishwanathan, K | 1 |
| Bartlett, MG | 1 |
| Stewart, JT | 1 |
| Logemann, CD | 1 |
| Rankin, LM | 1 |
| Sheftell, F | 1 |
| O'Quinn, S | 2 |
| Watson, C | 2 |
| Pait, D | 1 |
| Wheeler, SD | 1 |
| Gnecchi-Ruscone, T | 1 |
| Bernard, X | 1 |
| Pierre, P | 1 |
| Anderson, D | 1 |
| Winter, PD | 1 |
| Crisp, A | 2 |
| Melin, JA | 1 |
| Camici, PG | 1 |
| Powers, C | 1 |
| Szeto, S | 1 |
| Pangtay, D | 1 |
| Bort, T | 1 |
| Cervi, M | 1 |
| Cady, R | 2 |
| Bartleson, JD | 1 |
| Warner, JS | 1 |
| Havanka, H | 1 |
| Dahlöf, C | 1 |
| Pop, PH | 1 |
| Whitehouse, H | 1 |
| Boswell, D | 1 |
| Becker, W | 1 |
| Hauge, T | 1 |
| Mihout, B | 1 |
| Niewold, J | 1 |
| Tørring, J | 1 |
| Thaventhiran, L | 1 |
| Weintraub, JR | 1 |
| Valette, C | 1 |
| Potrebic, S | 1 |
| Raskin, NH | 1 |
| Frischer, M | 1 |
| Croft, P | 1 |
| Ellrich, J | 1 |
| Messlinger, K | 1 |
| Chiang, CY | 1 |
| Hu, JW | 1 |
| Christensen, ML | 1 |
| Eades, SK | 1 |
| Fuseau, E | 1 |
| Kempsford, RD | 1 |
| Phelps, SJ | 1 |
| Hak, LJ | 1 |
| Newman, L | 1 |
| Mannix, LK | 1 |
| Landy, S | 1 |
| Silberstein, S | 1 |
| Lipton, RB | 3 |
| Putnam, DG | 1 |
| Jöbsis, M | 1 |
| Batenhorst, A | 1 |
| Caro, JJ | 1 |
| Getsios, D | 1 |
| Raggio, G | 1 |
| Caro, G | 1 |
| Black, L | 1 |
| Hashimoto, S | 1 |
| Iwata, M | 1 |
| Marcus, DA | 1 |
| Jiang, K | 1 |
| Welch, KM | 1 |
| Connor, HE | 1 |
| Freitag, FG | 1 |
| Fité, B | 1 |
| López-Gil, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TreximetTM in the Prevention and Modification of Disease Progression in Migraine[NCT01300546] | Phase 4 | 40 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Self-assessed grade of compliance with lifestyle modification changes (where A=1, B=2, C=3, D=4, and F=5; lower scores represent better outcomes) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Day 121
| Intervention | scores on a scale (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | 2.33 |
| Naproxen Sodium | 2.43 |
Comparing the number of migraine headache days during Baseline Period Days 1-30 to number or migraine headache days reported in Treatment Period Days 91-120 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change=[ (total headache days during Treatment Period Month 3 (Days 91-120)-total headache days during Baseline (Days 1-30)/total headache days during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Day 121 (following 30 day Baseline Period and Treatment Period Days 91-120)
| Intervention | percent change of headache days (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | -13.50 |
| Naproxen Sodium | -36.50 |
Total number of doses of study medication reported taken per participant in Treatment Period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | doses of study medication (Mean) | ||
|---|---|---|---|
| Treatment Period Month 1 | Treatment Period Month 2 | Treatment Period Month 3 | |
| Naproxen Sodium | 9.36 | 8.86 | 8.50 |
| Sumatriptan/Naproxen Sodium | 11.00 | 10.28 | 10.28 |
Number of subjects with at least a 50% reduction in number of headache days reported in Baseline versus Treatment period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 3 | 3 | 6 |
| Sumatriptan/Naproxen Sodium | 1 | 2 | 3 |
Comparing the number of migraine attacks reported from Baseline to the number of migraine attacks reported in Treatment Period Months 1(Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Each treatment month percent change was individually compared to Baseline. The following formula was used for each treatment period calculation. e.g.,Percent change=[ (total migraine attacks days during Treatment Period Month 3 (Days 91-120)-total migraine attacks during Baseline (Days 1-30)/total migraine attacks during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine attacks (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -12.23 | -9.03 | -39.12 |
| Sumatriptan/Naproxen Sodium | -4.35 | -2.88 | -8.63 |
Number of subjects with at least a 50% reduction in number of migraine attacks reported in Baseline versus Treatment period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 1 | 0 | 6 |
| Sumatriptan/Naproxen Sodium | 3 | 2 | 4 |
"Change in MIDAS total score from end of Baseline (Day 31) to end Treatment Period month 3 (Day 121) in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Total score of disability ranges:~0 to 5, MIDAS Grade I, Little or no disability~6 to 10, MIDAS Grade II, Mild disability~11 to 20, MIDAS Grade III, Moderate disability~21+, MIDAS Grade IV, Severe disability No subscales are present." (NCT01300546)
Timeframe: Baseline MIDAS collected at Day 31, Post final dose study medication MIDAS collected at Day 121.
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline Day 31 | Day 121 | |
| Naproxen Sodium | 22.6 | 24.1 |
| Sumatriptan/Naproxen Sodium | 28.7 | 27.9 |
Comparing mean migraine duration from onset to painfree from Baseline(Days 1-30) to each month: Treatment Period Months 1 (Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from Treatment Period Month 3 and Baseline, then comparing the average change between each arm. The following formula was used for each treatment period calculation. e.g.,Percent change=[(mean duration from onset to painfree during Treatment Period Month 3 (Days 91-120)- mean duration from onset to painfree during Baseline (Days 1-30)/mean duration from onset to painfree during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -14.92 | -26.35 | 70.84 |
| Sumatriptan/Naproxen Sodium | 72.04 | 35.86 | 61.96 |
"% change from Baseline in mean migraine duration from time of treatment to pain free reported in Treatment Period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Percent change=[(mean duration from treatment to painfree during Treatment Period Month 3 (Days 91-120)- mean duration from treatment to painfree during Baseline (Days 1-30)/mean duration from treatment to painfree during Baseline (Days 1-30)]*100%)." (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -14.91 | -25.52 | 73.42 |
| Sumatriptan/Naproxen Sodium | 150.10 | 92.73 | 114.10 |
Comparing migraine severity 2 hours after treatment from Baseline(Days 1-30) to migraine severity reported 2 hours after treatment in Treatment Period Months 1 (Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from Treatment Period Month 3 and Baseline, then comparing the average change between each arm. The following formula was used for each treatment period calculation. e.g.,Percent change=[ (mean migraine severity during Treatment Period Month 3 (Days 91-120)- mean migraine severity during Baseline (Days 1-30)/mean migraine severity during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine severity (Mean) | ||
|---|---|---|---|
| 2 hours after treatment for Baseline to Month 1 | 2 hours after treatment for Baseline to Month 2 | 2 hours after treatment for Baseline to Month 3 | |
| Naproxen Sodium | 11.78 | 0.33 | 32.62 |
| Sumatriptan/Naproxen Sodium | -17.84 | -36.71 | -55.60 |
Comparing the number of migraine headache days during Baseline Period Days 1-30 to number or migraine headache days reported in Treatment Period Month 1 (Days 31-60), Treatment Period Month 2 (Days 61-90), and Treatment Period Month 3 (Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. e.g., Percent change=[ (total headache days during Treatment Period Month 3 (Days 91-120)-total headache days during Baseline (Days 1-30)/total headache days during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine headache days (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -26.86 | -21.44 | -36.50 |
| Sumatriptan/Naproxen Sodium | -1.70 | -4.39 | -13.50 |
% change in number of doses during Baseline of triptans (Group A) and non-steroidal anti-inflammatory drugs(NSAIDs) (Group B) vs. doses during Treatment Period Months 1, 2, and 3 of study medication in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. e.g.,Percent change=[(number of doses during Treatment Period Month 3 (Days 91-120)- number of doses during Baseline (Days 1-30)/number of doses during Baseline (Days 1-30)]*100%). The total number of subjects used in this analysis is different than the total number of subjects as the analysis is only looking at those subjects that were taking one of the study medications during Baseline. (NCT01300546)
Timeframe: Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of study medication (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 160.8 | 76.4 | 112.7 |
| Sumatriptan/Naproxen Sodium | 130.8 | 114.9 | 96.1 |
29 reviews available for naratriptan and Abdominal Migraine
| Article | Year |
|---|---|
Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review.
Topics: Animals; Migraine Disorders; Piperidines; Randomized Controlled Trials as Topic; Serotonin Receptor | 2021 |
Naproxen with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Drug Therapy, Combination; Humans; Migr | 2013 |
Triptans and migraine: advances in use, administration, formulation, and development.
Topics: Carbazoles; Humans; Migraine Disorders; Piperidines; Serotonin 5-HT1 Receptor Agonists; Serotonin Re | 2017 |
Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register.
Topics: Double-Blind Method; Germany; Humans; Migraine Disorders; Piperidines; Randomized Controlled Trials | 2011 |
Mechanisms of action of the 5-HT1B/1D receptor agonists.
Topics: Carbazoles; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Receptor | 2002 |
Naratriptan.
Topics: Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Receptor Agonists; Tryptamines | 2001 |
Comparative aspects of triptans in treating migraine.
Topics: Carbazoles; Cardiovascular Diseases; Humans; Indoles; Migraine Disorders; Oxazolidinones; Patient Sa | 2001 |
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
Topics: Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; | 2004 |
[Recent progress in therapy for migraine headache].
Topics: Anticonvulsants; Botulinum Toxins; Calcitonin Gene-Related Peptide; Central Nervous System; Clinical | 2004 |
[Meta-analysis of triptan treatment in migraine].
Topics: Carbazoles; Evidence-Based Medicine; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidine | 2004 |
Migraine headache.
Topics: Acute Disease; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Dicl | 2003 |
Migraine headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Ergotamine; Humans; Ibuprofen; Indoles; Migrain | 2004 |
Preclinical neuropharmacology of naratriptan.
Topics: Analgesia; Animals; Cardiovascular Diseases; Humans; Migraine Disorders; Piperidines; Serotonin Rece | 2005 |
[Naratriptan. A new medical option for the pharmacist].
Topics: Humans; Migraine Disorders; Piperidines; Serotonin Receptor Agonists; Tryptamines | 2007 |
Over-the-counter triptans for migraine : what are the implications?
Topics: Germany; Humans; Migraine Disorders; Nonprescription Drugs; Piperidines; Serotonin Receptor Agonists | 2007 |
Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.
Topics: Administration, Oral; Biological Availability; Humans; Infusions, Parenteral; Injections, Subcutaneo | 2007 |
Naratriptan: an alternative for migraine.
Topics: Animals; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Recep | 1999 |
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
Topics: Acute Disease; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Vasospasm; Drug Des | 1999 |
Acute management of migraine: triptans and beyond.
Topics: Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Serotonin Receptor Agoni | 1999 |
The scientific basis of medication choice in symptomatic migraine treatment.
Topics: Acute Disease; Choice Behavior; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorder | 1999 |
Newer intranasal migraine medications.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Non-Narcotic; Clinical Trials as Topic | 2000 |
Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Topics: Acute Disease; Carbazoles; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidine | 2000 |
Treatment of acute migraine attacks.
Topics: Analgesics; Ergotamine; Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Receptor Agonist | 2000 |
New abortive agents for the treatment of migraine.
Topics: Clinical Trials as Topic; Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperid | 2001 |
[Current topics: expectation for new triptans].
Topics: Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Serotonin Receptor A | 2001 |
Establishing a standard of speed for assessing the efficacy of the serotonin(1B/1D) agonists (triptans).
Topics: Analgesics, Non-Narcotic; Carbazoles; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; | 2001 |
Have the triptans fulfilled their promise?
Topics: Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Serotonin Receptor Agonists; Sumat | 2001 |
Comparison of rizatriptan and other triptans on stringent measures of efficacy.
Topics: Administration, Oral; Humans; Indoles; Migraine Disorders; Oxazolidinones; Patient Satisfaction; Pip | 2001 |
Acute treatment of migraine and the role of triptans.
Topics: Acute Disease; Blood Flow Velocity; Carbazoles; Clinical Trials as Topic; Drug Administration Routes | 2001 |
17 trials available for naratriptan and Abdominal Migraine
| Article | Year |
|---|---|
Theory-based analysis of clinical efficacy of triptans using receptor occupancy.
Topics: Humans; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Serotonin 5-HT1 Receptor Agon | 2014 |
Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study.
Topics: Activities of Daily Living; Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Ove | 2003 |
Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.
Topics: Adult; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Patient | 2003 |
Out-patient detoxification in chronic migraine: comparison of strategies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Chi-Square Distribution; Female; Headac | 2003 |
Naratriptan in the short-term prophylaxis of pure menstrual migraine.
Topics: Adolescent; Adult; Drug Evaluation; Dysmenorrhea; Female; Follow-Up Studies; Humans; Indoles; Middle | 2005 |
The combination of naratriptan and prochlorperazine in migraine treatment.
Topics: Adult; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Migrai | 2005 |
Efficacy of oral naratriptan in the treatment of menstrually related migraine.
Topics: Administration, Oral; Double-Blind Method; Female; Humans; Menstruation; Migraine Disorders; Pain Me | 2005 |
Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.
Topics: Adult; Female; Humans; Menstruation; Middle Aged; Migraine Disorders; Piperidines; Serotonin Recepto | 2007 |
Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Gastrointestinal Diseases; | 1997 |
Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Male; Middle | 1999 |
Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs.
Topics: Adult; Coronary Circulation; Female; Heart; Humans; Indoles; Male; Middle Aged; Migraine Disorders; | 2000 |
Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents.
Topics: Adult; Aged; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Patient Satisfaction; P | 2000 |
Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Indoles; Migraine Disorders; Patient | 2000 |
Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Indoles; Middle Ag | 2000 |
[Quality of life of migraine patients after treatment with 2.5 mg oral naratriptan].
Topics: Administration, Oral; Adult; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Piperid | 2000 |
Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine.
Topics: Adolescent; Area Under Curve; Child; Female; Humans; Indoles; Male; Migraine Disorders; Piperidines; | 2001 |
Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Double-Blind Method; Female; Humans; Indoles; Menstruation; Migraine Disorders; Piperidines; | 2001 |
66 other studies available for naratriptan and Abdominal Migraine
| Article | Year |
|---|---|
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzopyrans; Binding, Competitive; Cell Membrane; C | 1997 |
Pharmacological modulation of ventral tegmental area neurons elicits changes in trigeminovascular sensory processing and is accompanied by glycemic changes: Implications for migraine.
Topics: Animals; Blood Glucose; Male; Migraine Disorders; Neurons; Perception; Pituitary Adenylate Cyclase-A | 2022 |
Unrecognized challenges of treating status migrainosus: An observational study.
Topics: Adult; Dexamethasone; Female; Humans; Ketorolac; Male; Middle Aged; Migraine Disorders; Nerve Block; | 2020 |
Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding.
Topics: Adult; Breast Feeding; Female; Humans; Infant; Infant, Newborn; Migraine Disorders; Milk, Human; Oxa | 2021 |
Naratriptan in the Prophylactic Treatment of Cluster Headache.
Topics: Adult; Aged; Cluster Headache; Female; Humans; Japan; Male; Middle Aged; Migraine Disorders; Piperid | 2017 |
Naratriptan May Become an Alternative Prophylactic Option for Patients with Cluster Headache.
Topics: Cluster Headache; Humans; Indoles; Migraine Disorders; Piperidines; Tryptamines | 2017 |
Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
Topics: Abnormalities, Drug-Induced; Administrative Claims, Healthcare; Adolescent; Adult; Databases, Factua | 2018 |
[Publish your case report].
Topics: Acute Coronary Syndrome; Aged; Editorial Policies; Female; Humans; Medical Records, Problem-Oriented | 2013 |
Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: a Fos protein study.
Topics: Animals; Calcium Channels; Cerebellar Ataxia; Electric Stimulation; Gene Knock-In Techniques; Mice; | 2014 |
Long-acting triptans and weather-related migraines.
Topics: Adolescent; Carbazoles; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Male; Migrai | 2014 |
Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Drug Compounding; Drug Storage; Excip | 2014 |
[Myocardial ischemia caused by overuse of headache medications].
Topics: Combined Modality Therapy; Drug Substitution; Female; Humans; Middle Aged; Migraine Disorders; Myoca | 2014 |
Maximum effect of triptans in migraine? A comment.
Topics: Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Migraine Disorders; Pain Measure | 2008 |
Halide salts of antimigraine agents eletriptan and naratriptan.
Topics: Analgesics; Crystallography, X-Ray; Halogens; Humans; Hydrogen Bonding; Migraine Disorders; Molecula | 2008 |
Triptans and troponin: a case report.
Topics: Acute Coronary Syndrome; Aged; Electrocardiography; Female; Humans; Migraine Disorders; Piperidines; | 2009 |
Rizatriptan. Comparative trial results.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazolidinones; Pipe | 2000 |
Drug dependence associated with triptans and ergot derivatives: a case/non-case study.
Topics: Claviceps; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Oxazolidinones; Piperidines; P | 2010 |
Pure naratriptan-induced ischemic colitis: a case report.
Topics: Colitis, Ischemic; Female; Humans; Middle Aged; Migraine Disorders; Piperidines; Tryptamines; Vasoco | 2010 |
Safety of triptans for migraine headaches during pregnancy and breastfeeding.
Topics: Breast Feeding; Female; Humans; Migraine Disorders; Piperidines; Pregnancy; Pregnancy Complications; | 2010 |
Migraine-like headache in a patient with complement 1 inhibitor deficient hereditary angioedema.
Topics: Adult; Angioedemas, Hereditary; Brain; Complement C1 Inhibitor Protein; Danazol; Estrogen Antagonist | 2012 |
Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Female; Humans; Indoles; Male; Middle Aged; Migraine | 2002 |
[Ischemic colitis associated with naratriptan administration].
Topics: Colitis, Ischemic; Female; Humans; Indoles; Middle Aged; Migraine Disorders; Piperidines; Serotonin | 2002 |
[Early, but not unnecessarily frequent administration. What is proper timing for triptan drugs?].
Topics: Drug Administration Schedule; Humans; Indoles; Migraine Disorders; Pain Measurement; Piperidines; Se | 2003 |
Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases.
Topics: Adolescent; Adult; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Pain, Intractable | 2003 |
[A descriptive analysis of naratriptan use among migraineurs in ambulatory medicine].
Topics: Acute Disease; Adult; Ambulatory Care; Female; Follow-Up Studies; Humans; Indoles; Male; Migraine Di | 2003 |
Investigation of the effects of naratriptan, rizatriptan, and sumatriptan on jugular venous oxygen saturation in anesthetized pigs: implications for their mechanism of acute antimigraine action.
Topics: Anesthesia; Animals; Blood Gas Analysis; Hemodynamics; Indoles; Jugular Veins; Male; Migraine Disord | 2003 |
[Improved pharmacokinetics. Fast tryptan with sustained response].
Topics: Administration, Oral; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Female; Head | 2003 |
[Highly selective beginning. Associated symptoms and side effects in retrospect].
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Migraine D | 2003 |
Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy.
Topics: Action Potentials; Animals; Cats; Cerebrovascular Circulation; Electric Stimulation; Indoles; Microe | 2004 |
The sumatriptan/naratriptan aggregated patient (SNAP) database: aggregation, validation and application.
Topics: Clinical Trials as Topic; Data Collection; Databases, Factual; Humans; Indoles; Logistic Models; Mig | 2004 |
Correlation between lipophilicity and triptan outcomes.
Topics: Central Nervous System Diseases; Chemical Phenomena; Chemistry, Physical; Humans; Indoles; Migraine | 2005 |
Ischemic colitis associated with naratriptan and oral contraceptive use.
Topics: Adult; Colitis, Ischemic; Contraceptives, Oral; Drug Interactions; Female; Humans; Indoles; Migraine | 2005 |
Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat.
Topics: Algorithms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Humans; Mana | 2005 |
Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan.
Topics: Algorithms; Analgesics; Female; Humans; Male; Migraine Disorders; Models, Biological; Piperidines; S | 2005 |
[Medical treatment of migraine attacks in the child].
Topics: Acetaminophen; Age Factors; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Ergot Alkalo | 2006 |
Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target?
Topics: Afferent Pathways; Animals; Cerebral Arteries; Drug Interactions; Glutamic Acid; Male; Migraine Diso | 2006 |
[Prophylactic measures and acute treatment of migraine].
Topics: Anticonvulsants; Humans; Migraine Disorders; Piperidines; Serotonin Agents; Tryptamines | 2006 |
A model-based approach to treatment comparison in acute migraine.
Topics: Dose-Response Relationship, Drug; Humans; Markov Chains; Migraine Disorders; Models, Biological; Pip | 2006 |
Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Glutamic Acid; Headache Disorders; Headache D | 2007 |
[The Vigimig study of naratriptan use in general practice].
Topics: Adult; Drug Prescriptions; Drug Utilization; Family Practice; Female; France; Humans; Male; Migraine | 2007 |
Temporary confusion depending on the usage of naratriptan.
Topics: Confusion; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Migraine Disorders; Piperidines; | 2007 |
A triptan too far?
Topics: Acute Disease; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinon | 1998 |
Oral naratriptan approved for migraine attacks.
Topics: Drug Approval; Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Receptor Agonists; Trypta | 1998 |
Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hum | 1998 |
Coronary side-effect potential of current and prospective antimigraine drugs.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Child; Coronary Vessels; Dihydroergotamine; Ergotamine; Fe | 1998 |
When the migraine rx isn't working.
Topics: Administration, Oral; Adult; Contraindications; Female; Humans; Indoles; Migraine Disorders; Patient | 1998 |
New "triptans" and other drugs for migraine.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 1998 |
[Zolmitriptan].
Topics: Chemistry, Pharmaceutical; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidine | 1998 |
Headache after frequent use of serotonin agonists zolmitriptan and naratriptan.
Topics: Adult; Female; Headache; Humans; Indoles; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; | 1999 |
Naratriptan is effective and well tolerated in the acute treatment of migraine.
Topics: Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Piperidines; Tryptamines; Vasoconstri | 1999 |
[Pharmacy-clinic medication of the month. Naratriptan (naramig)].
Topics: Drug Administration Schedule; Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Receptor A | 1999 |
Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew.
Topics: Humans; Indoles; Migraine Disorders; Piperidines; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, | 1999 |
Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry.
Topics: Bufotenin; Chromatography, High Pressure Liquid; Humans; Indoles; Mass Spectrometry; Migraine Disord | 2000 |
Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.
Topics: Acute Disease; Adult; Aged; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Piperidi | 2000 |
Naratriptan prophylaxis of transformed migraine or hemicrania continua?
Topics: Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Receptor Agonists; Tryptamines; Vasocons | 2000 |
Triptans to the rescue: effective therapy for migraine headaches in the workplace.
Topics: Absenteeism; Adult; Cost-Benefit Analysis; Efficiency; Female; Humans; Indoles; Injections, Subcutan | 2000 |
Re: "Naratriptan in the prophylaxis of transformed migraine" (Sheftell FD Rapoport AM, Coddon DR. Headache.1999,39:506-510).
Topics: Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Receptor Agonists; Tryptamines; Vasocons | 2000 |
Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Migraine Disord | 2000 |
Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?
Topics: Cohort Studies; Depression; Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piper | 2000 |
Modulation of neuronal activity in the nucleus raphé magnus by the 5-HT(1)-receptor agonist naratriptan in rat.
Topics: Animals; Indoles; Male; Migraine Disorders; Neurons; Piperidines; Raphe Nuclei; Rats; Rats, Wistar; | 2001 |
Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis.
Topics: Canada; Cost-Benefit Analysis; Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Receptor | 2001 |
Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
Topics: Administration, Oral; Adult; Double-Blind Method; Humans; Indoles; Migraine Disorders; Nausea; Oxazo | 2001 |
Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience.
Topics: Contraindications; Coronary Circulation; Dose-Response Relationship, Drug; Humans; Indoles; Injectio | 2001 |
Looking forward: the expanding utility of sumatriptan and naratriptan.
Topics: Headache Disorders; Humans; Indoles; Migraine Disorders; Piperidines; Primary Health Care; Serotonin | 2001 |
Building on the sumatriptan experience: the development of naratriptan.
Topics: Administration, Oral; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, | 2001 |
Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain.
Topics: Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperidines; Prospective Studies; | 2002 |